The Georgetown Company is planning to construct a 185,000-sf life sciences center in the Hell's Kitchen district of Manhattan in New York City. Created in partnership with Beacon Capital and ZoE Life Sciences, the seven-story facility will provide purpose-built research environments for biomedical and pharmaceutical tenants. The highly collaborative structure will offer flexible floorplates starting at 31,000 sf that can accommodate a variety of lab and office configurations.
The Scientific Equipment and Furniture Association (SEFA) announced the winners of the Lab of the Year Award program in November of 2023. Recognizing the creation of an outstanding laboratory building or complex, the awards reflect the vital contributions of the entire project team, including the facility’s designers, engineers, contractors, material vendors, and client representatives.
Touchstone is constructing the Chapter Buildings in Seattle to provide Class A lab and office environments in the heart of the University District. Created in partnership with Portman Holdings and Lionstone Investments, the mixed-use project includes the creation of two buildings linked by an 8,000-sf pedestrian thoroughfare. Tenants will enjoy large, open floor plans of up to 31,000 sf with abundant natural light and operable windows.
Breakthrough Properties broke ground in October of 2023 on a 210,000-sf life sciences center in Oxford in the United Kingdom. Designed by Niazi Roden, Trinity by Breakthrough will provide 160,000 sf of Class A lab and office environments complemented by world-class amenities. The six-story facility will offer flexible floorplates of up to 40,000 sf serviced by robust mechanical and electrical systems. A jettied ground floor will create sheltered areas for informal interaction and exchange while maximizing the public outdoor landscape.
Ivanhoé Cambridge and Lendlease are constructing FORUM, a $545 million life sciences center in Boston. Designed by SGA, the nine-story, 350,000-sf building will provide state-of-the-art labs and offices for biomedical and pharmaceutical companies. Offering flexible floorplates spanning 50,000 sf, FORUM will feature a publicly accessible ground level with a café, a lounge, a community living room, and an art gallery.
Merck celebrated the official groundbreaking for the $1.3 billion London Discovery Research Centre in October of 2023. Created in partnership with Precis Advisory, the 10-story, 269,000-sf building will provide 180,000 sf of leased space for the company’s UK headquarters. The vibrant facility will feature state-of-the-art labs, offices, and collaboration spaces where approximately 180 researchers will work alongside 600 employees involved in business development, regulatory compliance, and clinical affairs.
Alexandria Real Estate Equities completed construction in November of 2023 on Moderna's global headquarters at One Kendall Square. Designed by NBBJ to be the most sustainable lab building in Cambridge, the 462,100-rsf facility will support the development of innovative mRNA vaccines and therapies. The Class A+ property integrates advanced R&D labs and offices with engaging gathering spaces to promote interaction and collaboration.
Trammell Crow Company will begin construction in late 2023 on a 234,000-sf life sciences center in Redwood City, Calif. Created in collaboration with joint venture partner CBRE Investment Management, the five-story facility will offer Class A lab and office environments for biomedical tenants. Advanced building systems will reduce carbon emissions while accommodating the demands of next-generation research programs, with sophisticated HVAC infrastructure supplying 100 percent outside air to enhance occupant wellbeing.
BeiGene is constructing a $700 million campus for biologics manufacturing and research in Hopewell, N.J. Sited on 42 acres at the Princeton West Innovation Campus, the next-generation complex will provide 400,000 sf of dedicated space for commercial-stage production of cancer therapies, with up to 16,000 liters of biologics capacity. A 100,000-sf lab building will house clinical R&D suites and collaborative office environments. As BeiGene's U.S.
McCord Development is planning to construct BioHub Two in northeast Houston. Comprising 500,000 sf of lab, office, and cGMP manufacturing space, the 45-acre campus will accommodate a total of seven structures offering built-to-suit environments for private companies. This dynamic nexus of innovation and discovery will catalyze synergies with San Jacinto College's planned Biotech Training Center, which will be located nearby.
Canary Wharf Group and Kadans will break ground in fall of 2023 on One North Quay, a £500 million life sciences center in London. Designed by KPF, the 823,000-sf tower will provide world-class lab and office environments for biomedical and pharmaceutical companies. Constructed to the highest technological standards, the 23-story vertical campus will leverage advanced infrastructure to accommodate the stringent demands of wet-bench chemistry and high-containment research programs.
Moderna is investing $322 million to create a state-of-the-art biomanufacturing center in Marlborough, Mass. Offering leading-edge environments for the production of innovative therapies and vaccines, the state-of-the-art facility will also include a cleanroom, labs, offices, and warehouse areas. The project involves the renovation of a two-story, 140,000-sf building that was purchased in spring of 2023 from Oxford Properties. Sited on 24 acres, the existing structure will be expanded to provide an additional 60,000 sf of space.
CellCarta, a leading provider of medical laboratory services, is partnering with developer Jadco to create a 450,000-sf life sciences center in Montreal. The $350 million project will transform the former site of the Montreal Chest Institute into Inspire Bio Innovations, a biomedical hub that will catalyze the development of new therapies and precision medicine technologies.
Ultragenyx opened a 110,000-sf gene therapy manufacturing facility in June of 2023 in Bedford, Mass. Advancing the creation of innovative treatments for rare genetic diseases, the sophisticated structure enables the large-scale manufacture of clinical-stage materials and approved products based on adeno-associated viral vectors (AAV). The highly efficient building integrates the company's proprietary Pinnacle PCL™ (producer cell line) platform which delivers optimal quality and scalability while reducing costs.
The Australian Institute for Infectious Disease (AIID) is planning to construct a state-of-the-art translational research facility in the Melbourne Biomedical Precinct. The Doherty Institute, the Burnet Institute, and the University of Melbourne are the founding partners for the AUD$650 million project, which will accommodate over 1,000 scientists, academics, professionals, and public health experts engaged in collaborative discovery.